Black Diamond Therapeutics

Historical price data

Black Diamond Therapeutics is a clinical-stage biotech founded in 2017 with a mission to move beyond the 'one drug, one mutation' model in oncology. Its proprietary MasterKey discovery platform identifies and targets families of mutations that share a common structural conformation, aiming to treat broader patient populations and overcome resistance. The company's strategy is focused on advancing its pipeline in areas of high unmet need, specifically NSCLC and GBM, while navigating the significant clinical and financial risks inherent in its early-stage, platform-driven approach.

The MasterKey platform is a structure-based drug discovery engine that designs small molecule therapies to target shared conformational states of mutant kinases, enabling one drug to address a broad family of oncogenic mutations.

Black Diamond competes with large pharma in EGFR (AstraZeneca, J&J) and a crowded field in KRAS (Amgen, Mirati/BMS, Revolution Medicines). Its differentiation hinges on the breadth of mutation coverage and CNS penetrance of its MasterKey inhibitors, aiming to occupy unique niches rather than engage in direct head-to-head competition.